Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 111 of 111 entries
View as:

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06293651 Org: User:
Start: 04/18/24 End: 10/31/29 Due: 10/31/30

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Phase: N/A Priority: Normal
NCT ID: NCT01674855 Org: User:
Start: 02/29/12 End: 05/31/13 Due: 05/31/14

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Phase: N/A Priority: Normal
NCT ID: NCT05743907 Org: User:
Start: 04/25/23 End: 03/10/25 Due: 03/10/26

The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients with Acquired Lumbar Spinal Stenosis

Phase: N/A Priority: Normal
NCT ID: NCT06654856 Org: User:
Start: 08/16/24 End: 10/31/25 Due: 10/31/26

Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT02754219 Org: User:
Start: 09/22/16 End: 01/19/18 Due: 01/19/19

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Phase: N/A Priority: Normal
NCT ID: NCT03910361 Org: User:
Start: 04/12/19 End: 07/02/20 Due: 07/02/21

Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05132049 Org: User:
Start: 12/18/21 End: 02/22/22 Due: 02/22/23

A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State

Phase: N/A Priority: Normal
NCT ID: NCT03944200 Org: User:
Start: 02/07/19 End: 03/25/19 Due: 03/25/20

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT05282069 Org: User:
Start: 05/12/22 End: 05/29/24 Due: 05/29/25

Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03200496 Org: User:
Start: 05/29/17 End: 06/29/17 Due: 06/29/18

Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis

Phase: N/A Priority: Normal
NCT ID: NCT03280927 Org: User:
Start: 11/10/17 End: 01/22/20 Due: 01/22/21